Herpes Simplex Program This Early Stage Program Uses A Vaxfectin-formulated Vaccine Against HSV-2

Herpes Simplex Program This early stage program uses a Vaxfectin-formulated vaccine against HSV-2 1

Herpes simplex research includes all medical research that attempts to prevent, treat, or cure herpes, as well as fundamental research about the nature of herpes. The vaccine is still in early stages of development and more research needs to be conducted before receiving FDA approval for clinical trials. Profectus BioSciences intends to use its PBS Vax therapeutic vaccine technology to engineer a vaccine for HSV-2. One vaccine that was under trial was Herpevac, a vaccine against HSV-2. Vical to Update Herpes Simplex Vaccine Program at Keystone Conference. Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial. Forward-looking statements include statements about the potential uses and benefits of Vical’s therapeutic HSV-2 vaccine, the parameters of the Phase 1/2 trial and timing regarding results from the Phase 1/2 trial. Overview & Active Programs.

Herpes Simplex Program This early stage program uses a Vaxfectin-formulated vaccine against HSV-2 2The company will now look to progress the program into clinical studies. Vaxfectin-formulated plasmid DNA vaccines against herpes simplex virus type 2, or HSV-2. At the moment there is no vaccine for HSV-2, with another candidate in development by GlaxoSmithKline (GSK) called Simplirix dropped from development after disappointing trials in 2012. Symptoms can be treated using antiviral medicines – such as acyclovir or famciclovir – which are used to hasten the healing of lesions and in some cases as a prophylactic therapy to prevent outbreaks. Agenus and Tomegavax all have candidates in early- to mid-stage clinical testing. Vical chief executive Vijay Samant said the company was disappointed by the results but would continue to monitor patients for efficacy over a nine-month period – and safety over 12 months – to enable us to determine the appropriate next steps for this programme. Improvements in T-cell responses by formulation and delivery mechanism. A unique method of using DNA for herpesvirus vaccine studies is to inject the DNA as a provirus, which has been modified to remove only one or a few genes., Beatriz 2000Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2.

The National Institutes of Health has completed Phase 1 clinical trials using the company’s vaccines targeting SARS, WNV, and Ebola. Prophylactic pDNA vaccines encoding HSV-2 glycoprotein D (gD) alone or encoding gD plus the HSV-2 tegument proteins UL46 and UL47 provided complete protection from both primary and recurrent disease (p Profile. Phase I/II clinical trial using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of recurrent genital herpes, and a completed preclinical program, with an allowed investigational. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68. Oct 2, 2014 Professor Ian Frazer is developing vaccines for herpes simplex and had early success in trials for a new jab to treat the herpes simplex virus.

ยป HSV-2

Prophylactic pDNA vaccines encoding HSV-2 glycoprotein D (gD) alone or encoding gD plus the HSV-2 tegument proteins UL46 and UL47 provided complete protection from both primary and recurrent disease (p. Independent Programs Targeting Infectious Diseases. HSV-2 is a member of the herpes virus family and is the cause of recurrent genital herpes worldwide. The company is planning to initiate a Phase I/II clinical trial of its Vaxfectin-formulated therapeutic vaccine against herpes simplex virus type 2 (HSV-2) before the end of 2013. using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of recurrent genital herpes, and a completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin. using its Vaxfectin formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of recurrent genital herpes, and a completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin. Vical’s Herpes Simplex Vaccines Protect Against Lethal Challenge and Demonstrate Significant Therapeutic Benefit in Animal Models. Vaxfectin(R)-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection. 3 million awarded to Vical in 2005 for the HSV-2 vaccine program under a Phase I STTR grant from the NIAID, which partially funded Vical’s initial development of the HSV-2 vaccine. We also plan to evaluate the HSV-2 vaccine with our novel Vaxfectin adjuvant. The NIH has transferred the IND for the SARS program to us and we are currently evaluating our options in continuing the development of a SARS vaccine. & 149; In August 2005, Merial advised us that initial trials of a pDNA melanoma vaccine for dogs have been completed and the vaccine is expected to receive approval for conditional USDA license use by early 2006. & 149; Also in April 2005, we were awarded two grants from the NIAID of the NIH for the partially funding of the development of a DNA vaccine against herpes simplex virus and a DNA Vaccine against influenza virus.

Vical Inc (vicl:nasdaq Cm): Company Description

Vical’s Herpes Simplex Vaccines Protect Against Lethal Challenge And Demonstrate Significant Therapeutic Benefit In Animal Models. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection. Vaxfectin -formulated vaccine, which encoded the HSV-2 glycoprotein D (gD2) antigen: Elicited antibody responses in 100 of mice against the encoded antigen;. (CMV), and a therapeutic DNA vaccine against herpes simplex virus type 2 (HSV-2). The company’s lead program is in the field of Malaria. As well, its pipeline, both in terms of independent programs and corporate collaborations as well as U. The available of flu vaccines produced using VICL’s DNA technology would solve this problem. Also important is the fact that the corporation continues to develop new formulations and delivery technologies, including the use of lipid molecules that can function as vaccine adjuvants. Perhaps the program of most interest to the Street now involves the Phase 3 trials of Vical’s Allovectin-7 for Stage III and IV melanoma. Now, there is no cure for genital herpes.